Skip to main content
. 2022 Aug 18;23(16):9305. doi: 10.3390/ijms23169305

Figure 2.

Figure 2

Anti-Tau strategies for the development of DMT. Passive immunotherapy is the main strategy under evaluation for reducing the cell-to-cell spread of extracellular Tau. At this moment specific phosphor-Tau mAbs are under clinical development. Other strategies such as active vaccination and antisense oligonucleotides to reduce Tau levels are also under evaluation in clinical trials.